CN116751296A - 一种靶向人肿瘤坏死因子α的纳米抗体及其应用 - Google Patents
一种靶向人肿瘤坏死因子α的纳米抗体及其应用 Download PDFInfo
- Publication number
- CN116751296A CN116751296A CN202310649112.9A CN202310649112A CN116751296A CN 116751296 A CN116751296 A CN 116751296A CN 202310649112 A CN202310649112 A CN 202310649112A CN 116751296 A CN116751296 A CN 116751296A
- Authority
- CN
- China
- Prior art keywords
- atnf
- seq
- amino acid
- acid sequences
- complementarity determining
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 title claims abstract description 25
- 102000057041 human TNF Human genes 0.000 title claims abstract description 18
- 230000008685 targeting Effects 0.000 title claims abstract description 10
- 239000000427 antigen Substances 0.000 claims abstract description 28
- 102000036639 antigens Human genes 0.000 claims abstract description 28
- 108091007433 antigens Proteins 0.000 claims abstract description 28
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims abstract description 21
- 230000002018 overexpression Effects 0.000 claims abstract description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 48
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 16
- 208000023275 Autoimmune disease Diseases 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 108091033319 polynucleotide Proteins 0.000 claims description 4
- 239000002157 polynucleotide Substances 0.000 claims description 4
- 102000040430 polynucleotide Human genes 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 abstract description 18
- 102000003298 tumor necrosis factor receptor Human genes 0.000 abstract description 18
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 13
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 13
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract description 7
- 239000002299 complementary DNA Substances 0.000 abstract description 5
- 230000003053 immunization Effects 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 3
- 241000123599 Hemiscylliidae Species 0.000 abstract description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 abstract description 2
- 238000010839 reverse transcription Methods 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 238000005406 washing Methods 0.000 description 9
- 235000020183 skimmed milk Nutrition 0.000 description 8
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 7
- 229960000723 ampicillin Drugs 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- 108091006020 Fc-tagged proteins Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108700012920 TNF Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000009137 competitive binding Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- PMUNIMVZCACZBB-UHFFFAOYSA-N 2-hydroxyethylazanium;chloride Chemical compound Cl.NCCO PMUNIMVZCACZBB-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241001489536 Chiloscyllium plagiosum Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282620 Hylobates sp. Species 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- AVWQQPYHYQKEIZ-UHFFFAOYSA-K trisodium;2-dodecylbenzenesulfonate;3-dodecylbenzenesulfonate;4-dodecylbenzenesulfonate Chemical compound [Na+].[Na+].[Na+].CCCCCCCCCCCCC1=CC=C(S([O-])(=O)=O)C=C1.CCCCCCCCCCCCC1=CC=CC(S([O-])(=O)=O)=C1.CCCCCCCCCCCCC1=CC=CC=C1S([O-])(=O)=O AVWQQPYHYQKEIZ-UHFFFAOYSA-K 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 239000007160 ty medium Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
Abstract
本发明涉及生物制药技术领域,尤其涉及一种靶向人肿瘤坏死因子α的纳米抗体及其应用。本发明使用重组的TNFα对条纹斑竹鲨进行免疫,外周血淋巴细胞总RNA反转录得到cDNA为模板扩增纳米抗体序列,最终分离获得4种纳米抗体,分别命名为aTNF‑6、aTNF‑9和aTNF‑15及aTNF‑21,4种纳米抗体具有不同的抗原互补决定区,SPR结果表明,四种纳米抗体均与人TNFα具有较高的亲和力,均可竞争性抑制TNFα与TNFR结合。本发明提供的纳米抗体有希望为体内TNFα过量表达治疗思路提供实验事实依据。
Description
技术领域
本发明涉及生物制药技术领域,尤其涉及一种靶向人肿瘤坏死因子α的纳米抗体及其应用。
技术背景
肿瘤坏死因子α(Tumor necrosis factor alpha,TNFα)是由巨噬细胞产生的一类炎症因子,是宿主防御的重要组成部分。机体在受到刺激或产生创伤时迅速释放大量肿瘤坏死因子,释放后TNFα在体内首先与细胞表面的肿瘤坏死因子受体(Tumor necrosisfactor receptor,TNFR)相结合,进而介导细胞内一系列生物学反应,如诱导细胞凋亡、激活NF-κB通路从而促进炎症相关蛋白的表达等,此细胞通路同时也介导拮抗细胞凋亡,所以体内正常的TNFα表达对机体的免疫调节具有重要意义,例如维持细胞稳态、抗感染等。但当肿瘤坏死因子持续分泌过量时则会导致免疫病理的产生,包括自身免疫性疾病和多种慢性炎症。
自身免疫性疾病(Autoimmune Diseases)是由于自身抗原免疫耐受缺失导致的一类慢性异质性疾病,可累及特定的靶器官或多个系统,不能正确识别抗原而导致攻击自身受体从而造成机体损害。自身免疫性疾病分为器官特异性自身免疫病和系统性自身免疫病,例如凸眼性甲状腺肿及重症肌无力、系统性红斑狼疮及类风湿性关节炎等。因此中和体内过量表达的TNFα是预防或治疗自身免疫性疾病的一种策略,通过拮抗结合过量浓度的TNFα,下调其与细胞表面受体结合浓度,从而减少与TNFα-TNFR介导病症相关症状,在一定程度上缓解自身免疫性疾病进程。
目前针对TNFα过表达所研发的治疗模式存在一定弊端,例如抗药性的产生,副作用明显等。能够靶向TNFα的生物小分子抑制剂是有望解决TNFα过表达的新途径。纳米抗体是存在于骆驼科和软骨鱼类体内的一种仅重链抗体,具有分子量小、结构简单、高特异性、高亲和力、便于与融合蛋白偶联及被标记物标记等优点,目前针对TNFα的纳米抗体尚无相关报导。
发明内容
为了解决现有技术中的问题,本发明的目的之一在于提供一种靶向人肿瘤坏死因子α的纳米抗体,所述纳米抗体为aTNF-6、aTNF-9、aTNF-15、aTNF-21中的任意一种,所述aTNF-6、aTNF-9、aTNF-15和aTNF-21均包含三个抗原互补决定区CDR1、CDR2和CDR3,其中:
所述aTNF-6的三个抗原互补决定区氨基酸序列分别为与SEQ ID NO:1、SEQ IDNO:2和SEQ ID NO:3所示的氨基酸序列同源性大于等于80%,优选为至少85%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%的氨基酸序列;
所述aTNF-9的三个抗原互补决定区氨基酸序列分别为与SEQ ID NO:4、SEQ IDNO:5和SEQ ID NO:6所示的氨基酸序列同源性大于等于80%,优选为至少85%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%的氨基酸序列;
所述aTNF-15的三个抗原互补决定区氨基酸序列分别为与SEQ ID NO:7、SEQ IDNO:8和SEQ ID NO:9所示的氨基酸序列同源性大于等于80%,优选为至少85%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%的氨基酸序列;
所述aTNF-21的三个抗原互补决定区氨基酸序列分别为与SEQ ID NO:10、SEQ IDNO:11和SEQ ID NO:12所示的氨基酸序列同源性大于等于80%,优选为至少85%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%的氨基酸序列。
上述同源性序列也包含与序列表所示序列相比具有一个或多个(优选1个、2个或3个)保守氨基酸突变(优选置换、插入或缺失)的氨基酸序列。
优选的,aTNF-6、aTNF-9、aTNF-15和aTNF-21的氨基酸序列分别如下:
aTNF-6的氨基酸序列:
aTNF-9的氨基酸序列:
aTNF-15的氨基酸序列:
aTNF-21的氨基酸序列:
上述纳米抗体的三个抗原互补决定区氨基酸序列CDR1、CDR2和CDR3分别如加粗画线部分所示,即:
aTNF-6的抗原互补决定区氨基酸序列:
CDR1:ILKGSSCALGSTHWY(SEQ ID NO:1)
CDR2:SDTKNTASKSF(SEQ ID NO:2)
CDR3:EAYTAGYCGGILYSYS(SEQ ID NO:3)
aTNF-9的三个抗原互补决定区氨基酸序列:
CDR1:VLRDSSCVLDSTDWY(SEQ ID NO:4)
CDR2:AETVNKASKSF(SEQ ID NO:5)
CDR3:KAYPDGRYCRSWGSYI(SEQ ID NO:6)
aTNF-15的三个抗原互补决定区氨基酸序列:
CDR1:VLRDSSCALDSTDWY(SEQ ID NO:7)
CDR2:AETVNKASKSL(SEQ ID NO:8)
CDR3:KVYPDGRYCRNWGSYI(SEQ ID NO:9)
aTNF-21的三个抗原互补决定区氨基酸序列:
CDR1:VLRDSSCVLDSTDWH(SEQ ID NO:10)
CDR2:AETVNKASKSF(SEQ ID NO:11)
CDR3:KAYPDGRYCRYWGSYI(SEQ ID NO:12)
本发明还提供一种靶向人肿瘤坏死因子α的抗体,其具有如上所述的aTNF-6、aTNF-9、aTNF-15、aTNF-21中的任意一种纳米抗体以及Fc结构域。
优选的,所述Fc结构域为人IgG1 Fc结构域,氨基酸序列如SEQ ID NO:17所示,编码所述氨基酸的核苷酸序列如SEQ ID NO:18所示。
本发明还提供一种多核苷酸,其编码如上所述的纳米抗体aTNF-6、aTNF-9、aTNF-15或aTNF-21,或编码如上所述的具有Fc结构域的抗体;其中编码aTNF-6的核苷酸序列如SEQ ID NO:19所示,编码aTNF-9的核苷酸序列如SEQ ID NO:20所示,编码aTNF-15的核苷酸序列如SEQ ID NO:21所示,编码aTNF-21的核苷酸序列如SEQ ID NO:22所示。
本发明还提供一种包含如上所述的多核苷酸的表达载体,以及一种包含如前所述的表达载体的宿主细胞,优选的,所述宿主细胞是用于表达外源蛋白的宿主细胞,例如细菌、酵母、昆虫细胞、哺乳动物细胞。
本发明提供一种药物组合物,其含有如上所述的纳米抗体aTNF-6、aTNF-9、aTNF-15或aTNF-21,或含有如上所述的具有Fc结构域的抗体。
本发明提供的纳米抗体/抗体可用于制备治疗和/或诊断TNFα过表达导致的自身免疫性疾病。
本发明的有益效果在于:
1、本发明使用重组的TNFα对条纹斑竹鲨进行了4次免疫,然后分离出外周血淋巴细胞,并抽提细胞的总RNA,随后反转录为cDNA,将cDNA用作模板以扩增纳米抗体序列,最终分离获得了4种纳米抗体,分别命名为aTNF-6、aTNF-9和aTNF-15及aTNF-21。
该纳米抗体(VHH)来源于天然的鲨鱼重链抗体,其具有1)结构简单、分子量小,有利于表达和使用;2)方便在大肠杆菌和各种真核系统中高效大量表达;3)由于其只有一个结合位点,属于单域抗体,作为诊断试剂有更好的通透性、特异性和检测线性;4)便于与各种融合蛋白偶联或更容易被各种标记物标记;5)更易于制备双功能抗体,更有利于靶向药物开发和细胞靶点定向运输;6)作为药物开发,其对于人免疫原性小,不容易产生免疫排斥等优点。
2、本发明提供的4种纳米抗体具有不同的抗原互补决定区,将结合人TNFα的抗体用哺乳动物细胞(293F)表达和分泌,将抗体与人IgG1 Fc融合,克隆至哺乳动物表达载体pTT5中,将载体转染哺乳动物细胞293F,培养5天后收集上清。采用Protein A柱子对上清中的融合蛋白进行纯化,4种纳米抗体的产量均大于80mg/L。
表面等离子共振实验(SPR)结果表明,四种纳米抗体均与人TNFα具有较高的亲和力,竞争性酶联免疫吸附实验结果表明均可竞争性的抑制TNFα与肿瘤坏死因子受体(TNFR)结合。本发明提供的纳米抗体有希望为体内TNFα过量表达治疗思路提供实验事实依据。
附图说明
图1为特异性结合人TNFα的V-C1结构域的单克隆噬菌体的ELISA结果。
图2为筛选的4种纳米抗体的柱层析结果。
图3为纳米抗体Fc融合蛋白及纳米抗体的SDS-PAGE凝胶电泳结果;图中泳道M为Marker,泳道1、3、5、7依次为纳米抗体aTNF-6、aTNF-9、aTNF-15和aTNF-21的Fc融合蛋白,泳道2、4、6、8是切除Fc的aTNF-6、aTNF-9、aTNF-15和aTNF-21纳米抗体。
图4为通过竞争性ELISA对纳米抗体与TNFR对hTNFα的竞争结合亲和力分析结果,图4中A显示了TNFR浓度与OD450值关系,图4中B显示了4种纳米抗体的EC50值。
图5为SPR检测纳米抗体与人TNFα的结合亲和力结果,图中KD为解离平衡常数;Ka为动力学缔合率,Kd为动力学解离速率。
具体实施方式
为了便于理解,下面结合实施例对本发明的技术方案做出更为具体的说明:
实施例1
纯化人TNFα用于免疫
1)通过E-Coli,BL21-Codon Plus(DE3)-RIPL菌株(Stratagene)表达人TNFα蛋白,通过亲和色谱和体积排阻色谱纯化得到目的蛋白。初次免疫使用弗氏完全佐剂,后面两次用弗氏不完全佐剂。每次用200μg/次的抗原剂量,按照抗原与佐剂体积比1:1混合,随后尾鳍皮下注射免疫条纹斑竹鲨(Chiloscyllium plagiosum)4次,间隔3周。
2)在第16周,收集血液以分离淋巴细胞,并分析针对人TNFα抗原的免疫反应。
3)使用Omega Biotek的RNA提取试剂盒提取淋巴细胞总RNA,并去除基因组DNA。使用Takara的PrimeScriptTMII第一链cDNA合成试剂盒,将RNA反转录为cDNA。
4)纳米抗体噬菌体展示文库的构建:使用PCR以上述cDNA为模板扩增获得纳米抗体的编码序列。采用吉布森组装法(Gibson assembly)将扩增的纳米抗体序列克隆至噬菌粒pR2的NcoI和NotI位点中。得到的吉布森组装产物即为初始纳米抗体噬菌体文库。
5)使用BTX ECM 399电穿孔仪转化大肠杆菌TG1感受态细胞:将噬菌体pR2纳米抗体基因(吉布森组装产物)在0.1cm的电穿孔比色皿中转化至大肠杆菌TG1感受态细胞中。将电穿孔产物(500μL)重悬于20mL LB培养基中,并在37℃,220rpm下孵育60分钟。将细菌涂布在5个150mm补充有100μg/ml氨苄青霉素和2%葡萄糖的TY(配方1L:16g胰蛋白胨、10g酵母提取物、5gNaCl)平板上以扩增噬菌体文库,在37℃下培养过夜。接下来,从平板上刮下转化菌落,与终浓度20%甘油旋涡充分混合,以1ml等分试样液氮速冻后在-80℃下保存,并计算噬菌体文库的大小(pfu/mL=OD260×100×22.14×1010)。
6)纳米抗体噬菌体展示文库的扩增:为了扩增纳米抗体的噬菌体文库,将0.2ml冷冻的文库在冰上融化,稀释到200ml的TY培养基中,该培养基中添加了100μg/ml的氨苄青霉素和2%的葡萄糖,并在37℃下培养。接下来,将1×1012pfu的KM13辅助噬菌体(购自MRC分子生物学实验室)添加到培养物中,并在37℃(水浴)中孵育45分钟。通过高速离心分离细胞沉淀,并重悬于200ml的2×TY培养基中,该培养基中添加了0.1%葡萄糖、50μg/mL卡那霉素和100μg/ml氨苄青霉素。将细胞在25℃,220rpm下孵育20小时以扩增噬菌体文库。离心后,将聚乙二醇(PEG)添加到培养上清液中以沉淀噬菌体颗粒。将沉淀的噬菌体颗粒沉淀溶解在PBS中,并在25%甘油的存在下于-80℃于1mL等分试样中保存。
7)平移:将纯化的人TNFα用PBS稀释至终浓度0.1mg/ml,并包被到96孔免疫板ELISA(Nunc maxsorp板)的一孔中,并留出一孔ELISA板用作阴性对照。用PBS洗涤3次后,将300μl MPBS(含5%脱脂牛奶的PBS)加入ELISA板的每个孔中,并在室温下孵育3小时以封闭未结合的位点。接下来,将板用PBS洗涤3次,并将含有针对hTNFα的1×1011pfu(在100μlMPBS中稀释)噬菌体库添加至每个孔,在室温下孵育后一小时后,用PBST(含0.1%Tween 20的PBS)洗涤3次。通过使用终浓度为0.5mg/ml的胰蛋白酶在室温下孵育一小时,将展示特异性针对hTNFα纳米抗体的噬菌体洗脱。将10μL洗脱的噬菌体添加到1ml大肠杆菌TG1感受态细胞中,并在37℃(水浴)中孵育45分钟以进行感染,然后将细菌培养物铺在补充了100μg/ml氨苄青霉素和2%葡萄糖的2×TY在37℃下孵育过夜。
8)单克隆噬菌体的制备:一轮淘选后,将48个单独的菌落挑入一个96孔圆底培养皿中,该培养皿中装有100μl的2×TY培养基,其中补充了100μg/ml的氨苄青霉素和2%的葡萄糖(w/v)。在37℃/180rpm持续孵育12个小时。接下来,将5μl该培养液接种至一个新的96孔圆底培养皿,该培养皿中装有200μl的2×TY培养基,其中补充了100μg/ml的氨苄青霉素和2%的葡萄糖(w/v)。将新鲜接种的板在37℃/250rpm下温育1.5小时,直到OD260为约0.5。将50μl包含4×108pfu KM13辅助噬菌体的2×TY培养基添加到平板的每个孔中,并在不摇动的情况下于37℃孵育45分钟以进行感染。感染后,弃去150μl上清液,并将剩余体积在3500g离心15分钟,弃去上清液,将细菌沉淀重悬于200ml的2×TY培养基中,该培养基中补充有100μg/ml氨苄青霉素、50μg/ml卡那霉素和0.1%葡萄糖(w/v),在25℃/250rpm下孵育过夜,最多20个小时。第二天,将培养物以3500g离心30分钟,然后将150μl上清液转移至新的96孔板中,并保存在4℃下,以备筛选纳米抗体。
9)噬菌体ELISA测试:用GFBE溶液将hTNFα稀释至0.1μg/mL,在Nunc96孔免疫板中每孔加入100μL,设立空白对照,4℃静置过夜。过夜包被的免疫板每孔加入260μL PBS洗2次,加入260μL MPBS室温封闭2h,封闭结束后每孔加入260μL PBS洗2次,分别取以上制备的单克隆phage 60μL与180μLMPBS混匀。各取100μL加入对照孔(先加)和包被抗原的孔(后加)中,置于桌面摇床上80rpm孵育1h。同时按照说明书用MPBS稀释HRP-anti M13抗体。孵育结束后,每孔加入260μL PBST洗4次,洗完加入100μL稀释的HRP-anti M13抗体,置于桌面摇床上以80rpm速度孵育1h,孵育完成后每孔加入100μLTMB显色,终止后用酶标仪测量OD450值,结果如图1所示。
10)将所有OD450nm值大于1的阳性克隆进行测序,引物序列为:5’-CCCTCATAGTTAGCGTAACGA-3’(SEQ ID NO:23),测序结果需反向互补。比对分析序列结果,排除重复克隆,最后确定4种对hTNFα蛋白特异的阳性噬菌体纳米抗体,分别命名为;aTNF-6(如SEQ ID NO:13所示的氨基酸序列)、aTNF-9(如SEQ ID NO:14所示的氨基酸序列)、aTNF-15(如SEQ ID NO:15所示的氨基酸序列)和aTNF-21(如SEQ ID NO:16所示的氨基酸序列),这4种纳米抗体具有与hTNFα结合的特定CDR区。
实施例2
纳米抗体-FC融合蛋白的表达和纯化
1)设计引导分泌的肽基因序列并将其融合到纳米抗体基因的N端,以保证表达后的分泌,将人IgG1 Fc融合到纳米抗体基因的C端,并将纳米抗体基因和人IgG1 Fc重新结合,然后克隆到哺乳动物表达载体pTT5中。
用聚乙烯亚胺(PEI)将构建载体转染到HEK293F(密度约2.5x 106细胞/ml)中,在FreestyleTM293表达培养基(购于永联生物)对转染后的哺乳动物细胞进行悬浮培养。将37℃ CO2培养箱(培养箱不宜过分干燥)摇床以150rpm的转速旋转,将哺乳动物细胞培养5天,然后通过2000rpm离心10分钟收集哺乳动物细胞培养物的上清液。用蛋白A柱纯化纳米抗体-FC融合蛋白,进行SDS-PAGE电泳分析,如图2所示,从上清液中获得了高纯度的纳米抗体-Fc融合蛋白。
2)将纯化的纳米抗体-FC融合蛋白进行TEV酶消化,以消化人IgG1 Fc的再结合位点,然后将混合物产物分别置于蛋白A柱和Ni柱中,没有FC产物的纳米体流经Protein A柱。分别用镍柱除去未消化的完全纳米抗体-Fc蛋白、Fc和TEV酶,收集流通液,浓缩,并进行SDS-PAGE电泳,如图3所示,在流通液中,得到高纯度的纳米抗体。
实施例3
纳米抗体与TNFR对hTNFα的竞争结合亲和力分析
将TNFα以2μg/mL的浓度包被至免疫板,4℃包被过夜。同时将TNFR蛋白按照说明书所示生物素化,以便于二抗结合。包被结束后洗板,每孔加入200μL PBS,甩掉后拍板至无明显液滴,重复3次,吸取200μL 5%的脱脂奶加入免疫板,室温封闭2h,将生物素化后的TNFR蛋白稀释至0.5μmol/L作为最大浓度,向低浓度3倍稀释,共稀释11个梯度。封闭结束后吸取稀释后的受体蛋白每孔加入100μL,对照孔加100μL脱脂奶,室温下孵育1h,结束后每孔加入260μL PBST溶液进行洗板,重复四次。洗板结束后将提前用5%的脱脂奶稀释好的二抗加入免疫板,每孔100μL,室温孵育1h,结束后每孔加入260μLPBST溶液进行洗板,重复四次,每孔加入100μL TMB显色液进行显色反应,5min后每孔加入50μL 1mol/L硫酸溶液进行终止,立即使用酶标仪测定OD450值。
根据TNFα与TNFR的ELISA结果,选定OD450值为1时的TNFR浓度作为竞争性ELISA实验中定量的值即为5nmol/L,选取抗体片段:aTNF-6、aTNF-9、aTNF-15、aTNF-21进行竞争性ELISA的实验,设定抗体最大浓度为2000nmol/L,向低浓度2倍稀释,共稀释10个梯度。将TNFα以2μg/mL的浓度包被至免疫板,4℃包被过夜,包被结束后洗板,每孔加入200μL PBS,甩掉后拍板至无明显液滴,重复3次,吸取200μL 5%的脱脂奶加入免疫板,室温封闭2h,将生物素化后的TNFR蛋白稀释至5nmol/L,封闭结束后吸取稀释后的抗体可变区蛋白和定量的TNFR竞争性的与TNFα结合,每孔加入100μL,阴性对照孔加100μL脱脂奶,阳性对照孔加100μL TNFR蛋白稀释液不加抗体,室温下孵育1h,结束后每孔加入260μL PBST溶液进行洗板,重复四次。洗板结束后将提前用5%的脱脂奶稀释好的二抗加入免疫板,每孔100μL,室温孵育1h,结束后每孔加入260μL PBST溶液进行洗板,重复四次,每孔加入100μL TMB显色液进行显色反应,5min后每孔加入50μL 1mol/L硫酸溶液进行终止,立即使用酶标仪测定OD450值。
图4显示四种纳米抗体均与hTNFα结合,并可以与天然受体TNFR竞争性的和hTNFα结合。图4中A显示了TNFR浓度与OD450值关系,图4中B结合结果显示,aTNF-6:EC50=397.6nM;aTNF-9:EC50=379.1nM;aTNF-15:EC50=415.8nM;aTNF-21:EC50=414.1nM。
实施例4
通过SRP表征纳米抗体与hTNFα蛋白之间的亲和力
材料:传感器芯片CM5,磷酸盐缓冲液加0.05%吐温20(0.05%TPBS),乙酸盐,pH5.0,hTNFα,抗hTNFα纳米抗体蛋白(aTNF-6,aTNF-9,aTNF-15和aTNF-21),乙醇胺-HCl封闭剂,10mM NaOH活化溶液,400mM MgCl2再生溶液。使用BiacoreTM T200系统(GEHealthcare)完成SPR实验分析,并使用0.05%TPBS作为样品缓冲液和运行缓冲液。所有分析温度均设置为25℃。使用胺偶联试剂盒pH 5.0进行hTNFα的固定化。
hTNFα固定在CM5芯片表面,纳米抗体作为流动相注入,当抗体流经芯片时,抗原与抗体特异性结合,导致芯片表面重量增加从而观察到分子间相互作用使用七个浓度(1000-15.875nM)的单循环动力学方法。通过从捕获试剂盒注入120s的再生溶液(400mM MgCl2)再生表面,以去除结合的纳米抗体。在每个纳米抗体中完成了纳米抗体+0.05%TPBS缓冲液注射+再生(空白循环)。首先从参考流通单元减去响应,然后减去空白周期的数据作为双重参考。通过使用BiacoreTMT200评估软件2.0选择了Kinetics方式拟合数据。
结果如图5所示,图5中A-D显示:aTNF-6的Ka(1/Ms)=2.38E10+4,Kd(1/s)=0.0018,KD(M)=7.54E10-8;aTNF-9的Ka(1/Ms)=1.09E10+5,Kd(1/s)=0.0017,KD(M)=1.55E10-8;aTNF-15的Ka(1/Ms)=1.79E10+5,Kd(1/s)=0.0018,KD(M)=1.028E10-8;aTNF-21的Ka(1/Ms)=2.04E10+5,Kd(1/s)=0.0011,KD(M)=5.21E10-9;制备的纳米抗体与TNFα结合的亲和力较高。
以上实施方式仅用以说明本发明的技术方案,而并非对本发明的限制;尽管参照前述实施方式对本发明进行了详细的说明,本领域的普通技术人员应当理解:凡在本发明创造的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明创造的保护范围之内。
Claims (9)
1.一种靶向人肿瘤坏死因子α的纳米抗体,其特征在于,所述纳米抗体为aTNF-6、aTNF-9、aTNF-15、aTNF-21中的任意一种,所述aTNF-6、aTNF-9、aTNF-15和aTNF-21均包含三个抗原互补决定区CDR1、CDR2和CDR3,其中:
所述aTNF-6的三个抗原互补决定区氨基酸序列分别为与SEQ ID NO:1、SEQ ID NO:2和SEQ ID NO:3所示的氨基酸序列同源性大于等于80%的氨基酸序列;
所述aTNF-9的三个抗原互补决定区氨基酸序列分别为与SEQ ID NO:4、SEQ ID NO:5和SEQ ID NO:6所示的氨基酸序列同源性大于等于80%的氨基酸序列;
所述aTNF-15的三个抗原互补决定区氨基酸序列分别为与SEQ ID NO:7、SEQ ID NO:8和SEQ ID NO:9所示的氨基酸序列同源性大于等于80%的氨基酸序列;
所述aTNF-21的三个抗原互补决定区氨基酸序列分别为与SEQ ID NO:10、SEQ ID NO:11和SEQ ID NO:12所示的氨基酸序列同源性大于等于80%的氨基酸序列。
2.如权利要求1所述的一种靶向人肿瘤坏死因子α的纳米抗体,其特征在于,所述aTNF-6的三个抗原互补决定区氨基酸序列分别如SEQ ID NO:1、SEQ ID NO:2和SEQ ID NO:3所示;aTNF-9的三个抗原互补决定区氨基酸序列分别如SEQ ID NO:4、SEQ ID NO:5和SEQ IDNO:6所示;aTNF-15的三个抗原互补决定区氨基酸序列分别如SEQ ID NO:7、SEQ ID NO:8和SEQ ID NO:9所示;所述aTNF-21的三个抗原互补决定区氨基酸序列分别如SEQ ID NO:10、SEQ ID NO:11和SEQ ID NO:12所示。
3.如权利要求2所述的一种靶向人肿瘤坏死因子α的纳米抗体,其特征在于,所述aTNF-6的氨基酸序列如SEQ ID NO:13所示,aTNF-9的氨基酸序列如SEQ ID NO:14所示,aTNF-15的氨基酸序列如SEQ ID NO:15所示,aTNF-21的氨基酸序列如SEQ ID NO:16所示。
4.一种靶向人肿瘤坏死因子α的抗体,其具有如权利要求1所述的aTNF-6、aTNF-9、aTNF-15、aTNF-21中的任意一种纳米抗体以及Fc结构域。
5.如权利要求4所述的抗体,其特征在于,所述Fc结构域为人IgG1 Fc结构域。
6.一种多核苷酸,其编码如权利要求1-3任一项所述的纳米抗体,或编码如权利要求4-5任一项所述的抗体。
7.一种表达载体,其包含如权利要求6所述的多核苷酸。
8.一种宿主细胞,其包含如权利要求7所述的表达载体。
9.权利要求1-3任一项所述的纳米抗体在制备治疗和/或诊断TNFα过表达导致的自身免疫性疾病中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310649112.9A CN116751296A (zh) | 2023-06-02 | 2023-06-02 | 一种靶向人肿瘤坏死因子α的纳米抗体及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310649112.9A CN116751296A (zh) | 2023-06-02 | 2023-06-02 | 一种靶向人肿瘤坏死因子α的纳米抗体及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116751296A true CN116751296A (zh) | 2023-09-15 |
Family
ID=87950636
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310649112.9A Pending CN116751296A (zh) | 2023-06-02 | 2023-06-02 | 一种靶向人肿瘤坏死因子α的纳米抗体及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116751296A (zh) |
-
2023
- 2023-06-02 CN CN202310649112.9A patent/CN116751296A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111647077B (zh) | 新型冠状病毒(sars-cov-2)刺突蛋白结合分子及其应用 | |
CN107216389B (zh) | 抗pd-l1纳米抗体及其编码序列和用途 | |
CN114276443B (zh) | 新型冠状病毒(sars-cov-2)刺突蛋白结合分子及其应用 | |
CN113121692B (zh) | 结合人rage胞外域的羊驼源抗体 | |
WO2009142460A2 (en) | Antibody-peptide fused synergibody | |
CN110144011B (zh) | 针对t淋巴细胞免疫球蛋白黏蛋白3的单域抗体 | |
EP3154564B1 (en) | New polypeptide | |
EP3154563B1 (en) | New polypeptide | |
CN110423277B (zh) | Pd-1的纳米抗体及其临床应用 | |
CN112625132B (zh) | 纳米抗体及其编码基因、表达载体、宿主细胞和应用 | |
CN108635579B (zh) | 抗人bFGF纳米抗体在制备治疗黑色素瘤药物中的应用 | |
WO2020248942A1 (zh) | 抗β-NGF纳米抗体及其应用 | |
CN116751296A (zh) | 一种靶向人肿瘤坏死因子α的纳米抗体及其应用 | |
KR101482237B1 (ko) | 항 il-6r 및 tnfr2을 포함하는 이중특이적 단백질을 발현하는 미니서클 벡터를 포함하는 자가 면역 질환 치료용 약학 조성물 | |
CN114249820B (zh) | 与SARS-CoV-2 RBD结合的羊驼源纳米抗体 | |
CN114249821B (zh) | 与SARS-CoV-2 RBD结合的羊驼源纳米抗体 | |
CN114249822B (zh) | 与SARS-CoV-2 RBD结合的羊驼源纳米抗体 | |
CN114369163B (zh) | 与人血小板衍生生长因子受体β结合的羊驼源纳米抗体 | |
CN114605555B (zh) | 一种抗新型冠状病毒SARS-CoV-2的双特异中和抗体及其应用 | |
KR101510831B1 (ko) | 항 il-6r 및 tnfr2을 포함하는 이중특이적 단백질을 발현하는 미니서클 벡터를 포함하는 줄기세포 치료제 | |
CN117088972A (zh) | 一种靶向SARS-CoV-2RBD蛋白的鲨源纳米抗体和应用 | |
CN106928357B (zh) | 一种CD105纳米抗体Nb86 | |
CN107236041B (zh) | Il-17抗体 | |
CN117467014A (zh) | 结合人免疫球蛋白E(IgE)的羊驼源纳米抗体 | |
CN114395036A (zh) | 一种抗脆弱拟杆菌毒素蛋白前体的特异性纳米抗体Nb2.82及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |